Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: Results and cost analysis

Cancer

Volumn 103, Issue 3, 2005, Pages 582-587

  Annibali, Ombretta ^a   Petrucci, Maria Teresa ^b   Martini, Vincenza ^b   Tirindelli, Maria Cristina ^a   Levi, Anna ^b   Fossati, Carolina ^a   Del Bianco, Patrizia ^b   Mandelli, Franco ^b   Foa, Robin ^b   Avvisati, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cyclophosphamide; Immunoglobulin M monoclonal gammopathy; Macroglobulinemia; Melphalan; Prednisone; Therapy; Waldenstr m macroglobulinemia

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN M; MELPHALAN; PARAPROTEIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MELPHALAN; MIDDLE AGED; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 19944433068     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20826     Document Type: Article

References (22)

1. Waldenström JG. Incipient myelomatotosis or "essential" hyperglobulinemia with fibrinogenopenia - a new syndrome? Acta Med Scand. 1944;117:216-247.
2. Waldenström JG. Macroglobulinemia: a review. Haematologica. 1986;71:437-441.
3. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinemia. Blood. 1994;83:1452-1459.
4. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18:214-226.
5. Ghobrial IM, Gertz MA, Fonseca R. Waldenström's macroglobulinaemia. Lancet Oncol. 2003;4:679-685.
6. Groves FD. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-94. Cancer. 1998;82:1078-1081.
7. Chen CI. Treatment for Waldenström's macroglobulinemia. Ann Oncol. 2004;15:550-558.
8. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmocytoid lymphoma, Waldenström's macroglobulinemia and mantle cell lymphoma. J Clin Oncol 1999;17:546-553.
9. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström's macroglobulinemia: results of a United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41-48.
10. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994;12:2694-2698.
11. Fridrik MA, Jäger G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström's disease with cladribine. Ann Hematol. 1997;74:7-10.
12. Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström's macroglobulinaemia. Br J Haematol. 1998;103:690-695.
13. Delannoy A, Van De Neste E, Michaux L, Bosly A, Ferrant A. Cladribine for Waldenström's macroglobulinaemia. Br J Haematol. 1999;104:933-934.
14. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Rodak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol. 1999;63:35-41.
15. Weber DM, Dimopoulos MA, Delasalle DK, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol. 2003;30:243-247.
16. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737-742.
17. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30:121-126.
18. Petrucci MT, Awisati G, Tribalto M, Giovangrossi P, Mandelli F. Waldenström's macroglobulinemia: results of combined oral treatment in 34 newly diagnosed patients. J Intern Med. 1989;226:443-447.
19. Case DC Jr., Ervin TJ, Boyd MA, Redfield DL. Waldenström's macroglobulinemia: long term results with the M-2 protocol. Cancer Invest. 1991;9:1-7.
20. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990;75:1928-1931.
21. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327-2333.
22. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol. 2002;19:3596-3601.